BidaskClub upgraded shares of Accelerate Diagnostics (NASDAQ:AXDX) from a hold rating to a buy rating in a report released on Tuesday morning.
A number of other analysts have also weighed in on the company. Zacks Investment Research raised Accelerate Diagnostics from a sell rating to a hold rating in a research report on Wednesday, February 21st. BTIG Research reaffirmed a hold rating on shares of Accelerate Diagnostics in a research report on Sunday, February 18th. Finally, ValuEngine lowered Accelerate Diagnostics from a hold rating to a sell rating in a research report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $33.00.
Accelerate Diagnostics stock opened at $24.45 on Tuesday. Accelerate Diagnostics has a twelve month low of $16.75 and a twelve month high of $30.45.
Accelerate Diagnostics (NASDAQ:AXDX) last posted its quarterly earnings data on Thursday, February 15th. The medical research company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. Accelerate Diagnostics had a negative return on equity of 54.66% and a negative net margin of 1,520.99%. The business had revenue of $2.10 million for the quarter. research analysts predict that Accelerate Diagnostics will post -1.2 earnings per share for the current year.
In other Accelerate Diagnostics news, Director Jack W. Schuler bought 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were purchased at an average price of $24.95 per share, with a total value of $499,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jack W. Schuler bought 15,000 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The stock was acquired at an average cost of $25.15 per share, for a total transaction of $377,250.00. The disclosure for this purchase can be found here. Insiders have bought 45,100 shares of company stock worth $1,130,850 in the last ninety days. Corporate insiders own 50.00% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. MetLife Investment Advisors LLC purchased a new position in Accelerate Diagnostics in the fourth quarter valued at $297,000. Raymond James & Associates increased its holdings in Accelerate Diagnostics by 73.7% in the fourth quarter. Raymond James & Associates now owns 38,291 shares of the medical research company’s stock valued at $1,003,000 after buying an additional 16,249 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Accelerate Diagnostics by 23.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 103,352 shares of the medical research company’s stock valued at $2,708,000 after buying an additional 19,606 shares during the last quarter. Deutsche Bank AG increased its holdings in Accelerate Diagnostics by 1,236.9% in the fourth quarter. Deutsche Bank AG now owns 312,470 shares of the medical research company’s stock valued at $8,185,000 after buying an additional 289,098 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC increased its holdings in Accelerate Diagnostics by 8.6% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 934,252 shares of the medical research company’s stock valued at $24,477,000 after buying an additional 73,770 shares during the last quarter. 44.89% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This story was first reported by Zolmax and is the property of of Zolmax. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://zolmax.com/investing/accelerate-diagnostics-axdx-upgraded-by-bidaskclub-to-buy/2134388.html.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.